---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-295027"
form_type: "8-K"
ticker: "AMGN"
cik: "0000318154"
company_name: "AMGEN INC"
filed_at: "2023-12-14T23:59:59+00:00"
generated_at: "2026-06-07T13:09:05.357276+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Amgen names James Bradner as EVP R&D/CSO; David Reese transitions to CTO

## Summary
- James Bradner, formerly President of Novartis Institutes for BioMedical Research, joins as EVP R&D and CSO effective Dec 18, 2023.
- David M. Reese moves from EVP R&D to newly created EVP and Chief Technology Officer role effective Dec 18, 2023.
- Both executives report to Chairman and CEO Robert A. Bradway.
- Reese will lead acceleration of AI and technology across Amgen; he was key architect of Amgen's AI initiatives.
- Announcement made Dec 14, 2023; appointments underscore Amgen's push to converge biotech and tech.

## SEC filing metadata
- accession: 0001193125-23-295027
- form_type: 8-K
- ticker: AMGN
- cik: 0000318154
- company_name: AMGEN INC
- filed_at: 2023-12-14T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318154/000119312523295027/0001193125-23-295027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318154/000119312523295027/d598661d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-295027
- JSON: https://secwatch.observer/filing/0001193125-23-295027.json
- Plain text: https://secwatch.observer/filing/0001193125-23-295027.txt

## Key facts
- Executive change
  James Bradner was appointed as Executive Vice President, Research and Development, and Chief Scientific Officer at AMGEN INC.
  - Action: hired
  - Role: Executive Vice President, Research and Development, and Chief Scientific Officer
  source text: James Bradner, M.D., has been hired as the Company’s Executive Vice President, Research and Development, and Chief Scientific Officer, an executive officer position.
  evidence_url: https://www.sec.gov/Archives/edgar/data/318154/000119312523295027/0001193125-23-295027-index.htm
- Executive change
  David M. Reese changed role as Executive Vice President and Chief Technology Officer at AMGEN INC.
  - Action: transition
  - Role: Executive Vice President and Chief Technology Officer
  source text: David M. Reese, M.D., will transition from Executive Vice President, Research and Development to Executive Vice President and Chief Technology Officer, a newly created executive officer position, responsible for accelerating the use of technology and artificial intelligence (AI) across all facets of Amgen Inc.
  evidence_url: https://www.sec.gov/Archives/edgar/data/318154/000119312523295027/0001193125-23-295027-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.